Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Pessimism Surrounds VEGF Inhibitors in Advanced Gastric Cancer
When a recent trial found that apatinib, an experimental VEGFR inhibitor, met its clinical endpoint and showed efficacy as a third-line therapy in treating advanced refractory stomach cancer, one might have expected at least two cheers. After all, gastric cancer is the third most fatal form of the disease globally, and there is currently no standard third-line treatment for advanced patients.
H Pylori Eradication Reduces Gastric Cancer Incidence in High-Risk Populations
A meta-analysis found that treatment of the bacterium H pylori with antibiotics in a population at high risk for stomach cancer is associated with a reduced incidence rate of stomach cancer.
Alcohol, Cured Meats, and Obesity Play a Role in Stomach Cancer, Study Finds
Drinking alcohol, eating processed meat, and being overweight can each increase an individual's chance of developing stomach cancer.
Immunotherapies Provide Promising Results in Advanced Gastric Cancer
Immunotherapies have been tested in melanoma, breast, prostate, kidney, and lung cancers, and are now being studied in advanced gastric cancers.
Keith T. Wilson, MD, Thomas F. Frist, Sr. Chair in Medicine, Professor, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center explains the link between helicobacter pylori (H pylori) and gastric cancer.
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell discusses novel targets in gastric cancer outside of HER2.
View More >


FDA Grants Accelerated Approval to Nivolumab for Hodgkin Lymphoma
FDA Grants Accelerated Approval to Nivolumab for Hodgkin Lymphoma
The FDA has granted an accelerated approval to nivolumab for patients with classical Hodgkin lymphoma following relapse or progression after autologous HSCT and post-transplantation brentuximab vedotin.
Understanding the Future of Immunotherapy in Melanoma
While there have been many recent advances in the field of melanoma regarding immunotherapy, there is still much more to come, says Antoni Ribas, MD, PhD.
Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL
With nearly a dozen new PI3K and BTK inhibitors currently in development, it is challenging to know which therapies are truly "next-generation" agents and which are "me too" products.
Shortcomings in SIRFLOX Design May Have Skewed PFS Findings
Shortcomings in the SIRFLOX study may have confounded the main findings, as the trial seemed plagued by a large number of confounding factors and a shifting trial design.
Novel Agent BION-1301 May Block Multiple Myeloma Cell Proliferation
BION-1301 may block multiple myeloma cell proliferation and reduce drug resistance and immunosuppression in the tumor microenvironment.